Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors-Reference-Cited by-同舟云学术

Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors

Published:2024-03-12 Issue:5 Volume:24 Page:325-333
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Appukkuttan Sreevalsa¹,Ko Gilbert¹,Fu Chunmay¹,Bannister Breyanne²,Kong Sheldon X.¹,Jhaveri Jay¹,Freedland Stephen J.³⁴

Affiliation:

1. Data Generation and Observational Studies, Bayer Healthcare, Whippany, NJ, USA

2. Market Access & Healthcare Consulting, Cencora, Conshohocken, PA, USA

3. Center for Integrated Research in Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, CA, USA

4. Section of Urology, Durham VA Medical Center, Durham, NC, USA

Funder

Bayer

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2024.2328778

Reference46 articles.

1. Cancer statistics, 2022

2. SEER. Cancer stat facts. 2021 [cited 2022 Sep 14]. Available from: https://seer.cancer.gov/statfacts/html/prost.html

3. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model

4. Characterising the castration-resistant prostate cancer population: a systematic review

5. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-Drug Interactions in Hospitalized Urological Patients: A Retrospective Cohort Study;Pharmacology;2024-07-30